skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 381  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Refined by: subject: Edema remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
Material Type:
Article
Add to My Research

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

The Lancet (British edition), 2022-02, Vol.399 (10326), p.741-755 [Peer Reviewed Journal]

2022 Elsevier Ltd ;Copyright © 2022 Elsevier Ltd. All rights reserved. ;2022. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)00018-6 ;PMID: 35085503

Full text available

2
KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema
Material Type:
Article
Add to My Research

KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema

American journal of ophthalmology, 2022-06, Vol.238, p.157-172 [Peer Reviewed Journal]

2022 ;Copyright © 2022. Published by Elsevier Inc. ;Copyright Elsevier Limited Jun 2022 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2022.01.004 ;PMID: 35038415

Full text available

3
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Material Type:
Article
Add to My Research

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

The New England journal of medicine, 2015-03, Vol.372 (13), p.1193-1203 [Peer Reviewed Journal]

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;Copyright © 2015 Massachusetts Medical Society. 2015 ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1414264 ;PMID: 25692915

Full text available

4
Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial
Material Type:
Article
Add to My Research

Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial

Archives of ophthalmology (1960), 2021-07, Vol.139 (7), p.701 [Peer Reviewed Journal]

Copyright American Medical Association Jul 2021 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2021.0606

Full text available

5
Early and Long-term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data
Material Type:
Article
Add to My Research

Early and Long-term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data

American journal of ophthalmology, 2016-12, Vol.172, p.72-79 [Peer Reviewed Journal]

2016 The Authors ;Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Dec 01, 2016 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2016.09.012 ;PMID: 27644589 ;CODEN: AJOPAA

Full text available

6
Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group
Material Type:
Article
Add to My Research

Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group

Eye (London), 2020-06, Vol.34 (Suppl 1), p.1-51 [Peer Reviewed Journal]

The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2020. ;The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2020 ;ISSN: 0950-222X ;EISSN: 1476-5454 ;DOI: 10.1038/s41433-020-0961-6 ;PMID: 32504038

Full text available

7
Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes
Material Type:
Article
Add to My Research

Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes

British journal of ophthalmology, 2021-02, Vol.105 (2), p.216-221 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2020-315933 ;PMID: 32265201

Full text available

8
Association of Ultra-Widefield Fluorescein Angiography–Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time
Material Type:
Article
Add to My Research

Association of Ultra-Widefield Fluorescein Angiography–Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time

Archives of ophthalmology (1960), 2022-10, Vol.140 (10), p.936 [Peer Reviewed Journal]

Copyright American Medical Association Oct 2022 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2022.3130

Full text available

9
Long-Term Visual Outcomes and Morphologic Biomarkers of Vision Loss in Eyes With Diabetic Macular Edema Treated With Anti-VEGF Therapy
Material Type:
Article
Add to My Research

Long-Term Visual Outcomes and Morphologic Biomarkers of Vision Loss in Eyes With Diabetic Macular Edema Treated With Anti-VEGF Therapy

American journal of ophthalmology, 2022-03, Vol.235, p.80-89 [Peer Reviewed Journal]

2021 Elsevier Inc. ;Copyright © 2021 Elsevier Inc. All rights reserved. ;2021. Elsevier Inc. ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2021.09.002 ;PMID: 34509431

Full text available

10
Association of Statin Therapy With Prevention of Vision-Threatening Diabetic Retinopathy
Material Type:
Article
Add to My Research

Association of Statin Therapy With Prevention of Vision-Threatening Diabetic Retinopathy

Archives of ophthalmology (1960), 2019-04, Vol.137 (4), p.363 [Peer Reviewed Journal]

Copyright American Medical Association Apr 2019 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2018.6399

Full text available

11
Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV
Material Type:
Article
Add to My Research

Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV

British journal of ophthalmology, 2017-03, Vol.101 (3), p.353-359 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/2017This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:http://creativecommons.org/licenses/by-nc/4.0 ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2017 ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2016-308668 ;PMID: 27215744

Full text available

12
Early Response to Anti–Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T
Material Type:
Article
Add to My Research

Early Response to Anti–Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T

American journal of ophthalmology, 2018-11, Vol.195, p.93-100 [Peer Reviewed Journal]

2018 Elsevier Inc. ;Copyright © 2018 Elsevier Inc. All rights reserved. ;COPYRIGHT 2018 Elsevier B.V. ;Copyright Elsevier Limited Nov 2018 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2018.07.030 ;PMID: 30077569

Full text available

13
Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti–Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial
Material Type:
Article
Add to My Research

Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti–Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial

Archives of ophthalmology (1960), 2019-04, Vol.137 (4), p.382 [Peer Reviewed Journal]

Copyright American Medical Association Apr 2019 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2018.6786

Full text available

14
Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial Setting
Material Type:
Article
Add to My Research

Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial Setting

American journal of ophthalmology, 2021-12, Vol.232, p.90-97 [Peer Reviewed Journal]

2021 Elsevier Inc. ;Copyright © 2021 Elsevier Inc. All rights reserved. ;2021. Elsevier Inc. ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2021.06.030 ;PMID: 34283986

Full text available

15
Effects of Crocin on Diabetic Maculopathy: A Placebo-Controlled Randomized Clinical Trial
Material Type:
Article
Add to My Research

Effects of Crocin on Diabetic Maculopathy: A Placebo-Controlled Randomized Clinical Trial

American journal of ophthalmology, 2018-06, Vol.190, p.89-98 [Peer Reviewed Journal]

2018 Elsevier Inc. ;Copyright © 2018 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jun 2018 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2018.03.007 ;PMID: 29550187

Full text available

16
Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema
Material Type:
Article
Add to My Research

Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema

American journal of ophthalmology, 2016-04, Vol.164, p.57-68 [Peer Reviewed Journal]

Elsevier Inc. ;2016 Elsevier Inc. ;Copyright © 2016 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Apr 2016 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2015.12.025 ;PMID: 26802783 ;CODEN: AJOPAA

Full text available

17
Next-generation anti-VEGF agents for diabetic macular oedema
Material Type:
Article
Add to My Research

Next-generation anti-VEGF agents for diabetic macular oedema

Eye (London), 2022-02, Vol.36 (2), p.273-277 [Peer Reviewed Journal]

2021. The Author(s), under exclusive licence to The Royal College of Ophthalmologists. ;The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2021. ;The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2021 ;ISSN: 0950-222X ;EISSN: 1476-5454 ;DOI: 10.1038/s41433-021-01722-8 ;PMID: 34373607

Full text available

18
Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries
Material Type:
Article
Add to My Research

Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries

British journal of ophthalmology, 2019-08, Vol.103 (8), p.1072-1077 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2019 ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2018-312284 ;PMID: 30242062

Full text available

19
Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study
Material Type:
Article
Add to My Research

Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study

American journal of ophthalmology, 2017-08, Vol.180, p.110-116 [Peer Reviewed Journal]

2017 Elsevier Inc. ;Copyright © 2017 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Aug 1, 2017 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2017.05.024 ;PMID: 28579062

Full text available

20
Vision Outcomes Following Anti–Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice
Material Type:
Article
Add to My Research

Vision Outcomes Following Anti–Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice

American journal of ophthalmology, 2018-07, Vol.191, p.83-91 [Peer Reviewed Journal]

2018 The Authors ;Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jul 2018 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2018.04.010 ;PMID: 29684329

Full text available

Results 1 - 20 of 381  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (380)

Refine My Results

Creation Date 

From To
  1. Before 2011  (8)
  2. 2011 To 2013  (11)
  3. 2014 To 2016  (37)
  4. 2017 To 2020  (160)
  5. After 2020  (166)
  6. More options open sub menu

Language 

  1. Japanese  (47)
  2. Turkish  (1)
  3. Norwegian  (1)
  4. More options open sub menu

Searching Remote Databases, Please Wait